Evidence map›Paper›PMID 40588996›Full record

ReviewCurrent pharmaceutical design2026

Elucidating the Complex Etiology of Schizophrenia: Comprehensive Insights into the Therapeutic Roles of Natural Compounds and Pharmacological Interventions.

Md Ali Mujtaba, Purushottam Gangane, Mohammed Kaleem, Naiyer Shahzad, Ali F Almutairy, Anwar Abbas N Alshmmari, Mandar Thool, Wasim Ahmad, Turky Omar Asar, Ameeduzzafar Zafar and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current pharmaceutical design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Md Ali MujtabaDepartment of Pharmaceutics, Faculty of Pharmacy, Northern Border University, Arar, Saudi Arabia.ORCID 0000-0002-6372-890X
Purushottam GanganeDepartment of Pharmaceutics, Dadasaheb Balpande College of Pharmacy, Rashtrasant Tukadoji Maharaj Nagpur University, Nagpur, 440037, India.ORCID 0000-0001-6260-0747
Mohammed KaleemDepartment of Pharmacology, Dadasaheb Balpande College of Pharmacy, Rashtrasant Tukadoji Maharaj Nagpur University, Nagpur, 440037, India.ORCID 0000-0003-4681-2031
Naiyer ShahzadDepartment of Pharmacology and Toxicology, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia.
Ali F AlmutairyDepartment of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraydah, 51452, Saudi Arabia.ORCID 0009-0007-7954-4893
Anwar Abbas N AlshmmariDepartment of Pharmaceutical Care, Security Forces Hospital, Dammam, 31413, Saudi Arabia.
Mandar ThoolDepartment of Pharmaceutics, Dadasaheb Balpande College of Pharmacy, Rashtrasant Tukadoji Maharaj Nagpur University, Nagpur, 440037, India.
Wasim AhmadDepartment of Kuliyate Tib, National Institute of Unani Medicine, Kottigepalya, Bengaluru, 560091, India.
Turky Omar AsarDepartment of Biology, College of Science and Arts at Alkamil, University of Jeddah, Jeddah, 23218, Saudi Arabia.
Ameeduzzafar ZafarDepartment of Pharmaceutics, College of Pharmacy, Jouf University, Sakaka, 72341, Al-Jouf, Saudi Arabia.
Danish MahmoodDepartment of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraydah, 51452, Saudi Arabia.

Funding

Deanship of Scientific Research at Northern Border University, Arar, KSA NBU-FFR-2025-2474-01
6 · The paper itself

Abstract

Schizophrenia (SCZ) remains a captivating mental disorder marked by complex symptomatology. Despite the success of the current therapeutic options for psychosis, a definitive cure remains elusive. Hence, this review explores mechanisms underlying SCZ pathophysiology, examining their potential as novel therapeutic targets. This is a narrative review of literature that has been critically analyzed following retrieval from PubMed, PubMed Central, and Google Scholar. Nearly 30% of patients of SCZ show no response to firstand second-generation antipsychotic drugs and continue to suffer from cognitive and negative symptoms, including medication-induced adverse effects. Apart from the social and environmental factors, SCZ has been strongly linked to epigenetic factors and alterations in protein expression. Epigenetic modifications include histone modification and DNA methylation. Epigenetic alterations gained through environmental factors, known as molecular scars, also influence, to some extent, the brain functions throughout the life span of a human being. Epigenetic mechanisms are now recognized as significant contributors to the development and progression of SCZ. Epigenetics is critical in SCZ etiology through DNA methylation and histone modification. Herbal medicines offer promise by targeting genetic and epigenetic pathways, albeit with safety concerns. These approaches offer potential as supplementary therapies alongside conventional treatments or alternative preventive measures. By thoroughly investigating these methods, we may uncover new possibilities in SCZ care, ultimately paving the path for more effective and holistic therapeutic approaches.

Indexed as

Antipsychotic AgentsBiological ProductsSchizophreniaAnimalsDNA MethylationEpigenesis, GeneticHumansAntipsychotic AgentsBiological ProductsDNA methylationepigenetic mechanismsetiological factorshistone modificationnatural drugs.Schizophrenia

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.